Serum cross-reactive thymosin alpha 1 levels in rats during induction of mammary carcinoma with 7,12-dimethylbenz[a]anthracene: short- and long-term effects.
Kurl. R N RN; Naylor. P H PH; Barsoum. A L AL
Key Findings
- CRT alpha 1 spikes within 2 hours after DMBA exposure
- Levels stay elevated for about 3 weeks, then return to control levels
- A second increase occurs at 9‑11 weeks when mammary tumors are palpable, followed by a slight decline but remaining above baseline
Practical Outcomes
- The findings hint that thymosin‑alpha‑1 levels change with tumor development, so it might serve as a biomarker in animal studies, but they offer no guidance on dosing, safety, or performance benefits for humans. Biohackers get no actionable protocol from this work.
Summary
In rats given a cancer‑causing chemical, the natural peptide thymosin‑alpha‑1 in the blood rose quickly, stayed high for a few weeks, dropped back to normal, then rose again when tumors became visible. The study only measured the body’s own peptide levels, not the effects of taking it as a supplement.
Abstract
The levels of serum cross-reactive thymosin alpha 1 (CRT alpha 1) were measured at various time intervals during the course of development of mammary tumors in female Sprague-Dawley rats intubated with 7,12-dimethylbenz[a]-anthracene (DMBA; 10 mg/rat). Matched control rats were also tested simultaneously. An increase in CRT alpha 1 in DMBA-treated animals was observed within 2 h of DMBA treatment. Thereafter the levels of CRT alpha 1 in the serum of the DMBA-treated rats remained elevated for another 3 weeks prior to declining to control levels. Levels remained stationary until an increase in serum CRT alpha 1 was observed at 9-11 weeks post-DMBA treatment. This correlated with the time when mammary tumors were either palpable or observed. Levels of CRT alpha 1 fell at 13 weeks but remained slightly elevated until sacrifice due to tumor burden at 18 weeks.
Study Information
pubmed
1993
1993-05-14T00:00:00.000Z
10.1016/0304-3835(93)90173-7
6